A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY COMPARING THE EFFICACY, SAFETY, AND TOLERABILITY OF SUBCUTANEOUS ADMINISTRATION OF FREMANEZUMAB VERSUS PLACEBO FOR THE PREVENTIVE TREATMENT OF CHRONIC MIGRAINE IN PEDIA
- Registry ID
- TV48125-CNS-30082
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Study type
- INTERVENTIONAL
- Sponsor
- TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D INC
- Start date
- 2022-06-06
- Last update
- 2020-11-10
Conditions
Related clinical trials
- A MULTICENTRE, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE ESCALATION
AND DOSE FINDING PHASE II STUDY TO EVALUATE THE SAFETY AND EFFICACY OF IPN10200
IN THE PREVENTION OF EPISODIC OR CHRONIC MIGRAINE IN ADULTS (MERANTI)
- A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, CLINICAL TRIAL
WITH EXTENSION PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF XEOMIN® INJECTIONS
FOR THE PREVENTION OF CHRONIC MIGRAINE
- A PHASE 3, MULTICENTER, 12-WEEK, DOUBLE BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ATOGEPANT FOR THE PREVENTIVE TREATMENT OF CHRONIC MIGRAINE IN PEDIATRIC SUBJECTS 12 TO 17 YEARS OF AGE
- A PHASE III, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTRE, PARALLEL-GROUP STUDY
WITH EXTENSION PHASE TO EVALUATE THE EFFICACY AND SAFETY OF DYSPORT® FOR THE PREVENTION OF
CHRONIC MIGRAINE IN ADULT PARTICIPANTS
- INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF IV EPTINEZUMAB IN ADOLESCENTS (12-17 YEARS) FOR THE PREVENTIVE TREATMENT OF CHRONIC MIGRAINE
- LONG TERM, OPEN LABEL (DOSE BLINDED), EXTENSION STUDY OF EPTINEZUMAB IN CHILDREN AND ADOLESCENTS WITH CHRONIC OR EPISODIC MIGRAINE
View on source registry